The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
The company saw $1.0 million in revenues for the quarter, including $976,000 from commercial testing, and attributed the growth to its pathology partnership initiative.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.
Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.
The company believes that blood-based exome sequencing can increase the applicability of its Signatera assays and could serve as a reflex to interrogate detected recurrences.
The investment bank gave the liquid biopsy company a price target of $90 and said that it views Guardant as the field leader.
As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.